NO20054336L - Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer - Google Patents
Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommerInfo
- Publication number
- NO20054336L NO20054336L NO20054336A NO20054336A NO20054336L NO 20054336 L NO20054336 L NO 20054336L NO 20054336 A NO20054336 A NO 20054336A NO 20054336 A NO20054336 A NO 20054336A NO 20054336 L NO20054336 L NO 20054336L
- Authority
- NO
- Norway
- Prior art keywords
- component
- asthma
- allergic
- inflammatory diseases
- methods
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title abstract 3
- 208000006673 asthma Diseases 0.000 title abstract 3
- 208000010668 atopic eczema Diseases 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 102000004452 Arginase Human genes 0.000 abstract 2
- 108700024123 Arginases Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 102000001733 Basic Amino Acid Transport Systems Human genes 0.000 abstract 1
- 108010015087 Basic Amino Acid Transport Systems Proteins 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037353 metabolic pathway Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45139603P | 2003-03-04 | 2003-03-04 | |
| US47587003P | 2003-06-05 | 2003-06-05 | |
| PCT/US2004/006470 WO2005003164A2 (en) | 2003-03-04 | 2004-03-04 | Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054336D0 NO20054336D0 (no) | 2005-09-20 |
| NO20054336L true NO20054336L (no) | 2005-12-02 |
Family
ID=33567303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054336A NO20054336L (no) | 2003-03-04 | 2005-09-20 | Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040234517A1 (pt) |
| EP (1) | EP1599587A2 (pt) |
| JP (1) | JP2007537984A (pt) |
| KR (1) | KR20050106483A (pt) |
| AU (1) | AU2004253846A1 (pt) |
| BR (1) | BRPI0408004A (pt) |
| CA (1) | CA2517684A1 (pt) |
| MX (1) | MXPA05009251A (pt) |
| NO (1) | NO20054336L (pt) |
| RU (2) | RU2005130636A (pt) |
| WO (1) | WO2005003164A2 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007005620A2 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Arginase ii: a target treatment of aging heart and heart failure |
| EP1913401A4 (en) * | 2005-08-03 | 2009-11-18 | Astrazeneca Ab | METHOD FOR IDENTIFYING AN AGENT THAT MODULATES TRANSPORTATION OF ARGININE IN A CHONDROCYTE |
| JP2009511586A (ja) * | 2005-10-11 | 2009-03-19 | ワシントン・ユニバーシティ | 気道分泌過多を治療するための組成物および方法 |
| EP2083812B1 (en) * | 2006-11-21 | 2017-04-05 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
| WO2008091814A2 (en) * | 2007-01-22 | 2008-07-31 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
| DE602007013691D1 (de) * | 2007-03-06 | 2011-05-19 | Rachid Ennamany | Zusammensetzung auf Basis von Rutin und L-Lysin |
| US8541183B2 (en) | 2007-09-11 | 2013-09-24 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
| KR101900016B1 (ko) * | 2009-03-12 | 2018-09-20 | 캔서 프리벤션 앤 큐어, 리미티드 | 폐 질환의 동정, 평가, 예방 및 치료 방법과, 성별에 기초하는 질환의 동정, 평가, 예방 및 치료를 포함하는 상기 방법의 키트 |
| GB201007556D0 (en) * | 2010-05-06 | 2010-06-23 | Wetenschappelijk En Tech Ct Va | Methods and compositions for textile layers and coatings |
| CA2799207C (en) * | 2010-05-26 | 2019-03-26 | Curna, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| WO2011163499A2 (en) * | 2010-06-23 | 2011-12-29 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| CN110709936A (zh) | 2017-04-04 | 2020-01-17 | 肺癌蛋白质组学有限责任公司 | 用于早期肺癌预后的基于血浆的蛋白质概况分析 |
| MX2023002285A (es) * | 2020-08-26 | 2023-05-16 | Cila Therapeutic Inc | Agentes terapeuticos inhalables. |
| WO2026064592A1 (en) * | 2024-09-20 | 2026-03-26 | Soufflé Therapeutics, Inc. | Oligonucleotide-mediated knockdown of slc6a19 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
| WO1983001451A1 (en) * | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4638045A (en) * | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5266464A (en) * | 1988-02-10 | 1993-11-30 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
| US4980281A (en) * | 1988-02-10 | 1990-12-25 | Housey Gerard M | Method of screening for protein inhibitors and activators |
| US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
| US5459039A (en) * | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US6784163B1 (en) * | 1990-04-13 | 2004-08-31 | Macleod Carol L. | Inhibition of cationic amino acid transporter protein and uses thereof |
| US5866123A (en) * | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
| GB9509757D0 (en) * | 1995-05-13 | 1995-07-05 | Ilford Ltd | Toning of photographic print material |
| AU2001285232A1 (en) * | 2000-08-24 | 2002-03-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| WO2003073990A2 (en) * | 2002-03-01 | 2003-09-12 | Children's Hospital Medical Center | Treatment for asthma or allergies |
| AU2003218099A1 (en) * | 2002-03-12 | 2003-09-29 | Lsu Medical Center | Modulation of the immune response through the manipulation of arginine levels |
| JP4723476B2 (ja) * | 2003-02-14 | 2011-07-13 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療 |
-
2004
- 2004-03-04 MX MXPA05009251A patent/MXPA05009251A/es not_active Application Discontinuation
- 2004-03-04 US US10/792,280 patent/US20040234517A1/en not_active Abandoned
- 2004-03-04 WO PCT/US2004/006470 patent/WO2005003164A2/en not_active Ceased
- 2004-03-04 JP JP2006532310A patent/JP2007537984A/ja active Pending
- 2004-03-04 RU RU2005130636/13A patent/RU2005130636A/ru unknown
- 2004-03-04 AU AU2004253846A patent/AU2004253846A1/en not_active Withdrawn
- 2004-03-04 KR KR1020057016407A patent/KR20050106483A/ko not_active Ceased
- 2004-03-04 BR BRPI0408004-1A patent/BRPI0408004A/pt not_active IP Right Cessation
- 2004-03-04 CA CA002517684A patent/CA2517684A1/en not_active Abandoned
- 2004-03-04 EP EP04717353A patent/EP1599587A2/en not_active Ceased
-
2005
- 2005-09-20 NO NO20054336A patent/NO20054336L/no not_active Application Discontinuation
-
2008
- 2008-10-24 US US12/257,852 patent/US20090156537A1/en not_active Abandoned
- 2008-11-18 RU RU2008145510/14A patent/RU2008145510A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050106483A (ko) | 2005-11-09 |
| RU2008145510A (ru) | 2010-05-27 |
| WO2005003164A3 (en) | 2005-05-12 |
| CA2517684A1 (en) | 2005-01-13 |
| WO2005003164A9 (en) | 2006-07-20 |
| NO20054336D0 (no) | 2005-09-20 |
| BRPI0408004A (pt) | 2006-02-14 |
| RU2005130636A (ru) | 2006-05-10 |
| EP1599587A2 (en) | 2005-11-30 |
| MXPA05009251A (es) | 2005-10-19 |
| US20040234517A1 (en) | 2004-11-25 |
| WO2005003164A2 (en) | 2005-01-13 |
| JP2007537984A (ja) | 2007-12-27 |
| US20090156537A1 (en) | 2009-06-18 |
| AU2004253846A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054336L (no) | Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer | |
| Yuan et al. | Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters | |
| EA201001821A1 (ru) | Производные триазола, полезные для лечения заболеваний | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| EA200870380A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета | |
| DE602007009839D1 (de) | Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| NO20084005L (no) | Aminderivater | |
| WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| UY32062A (es) | Inhibidores de beta-secretasa | |
| EP1921917A4 (en) | CONDENSED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| EP1819674A4 (en) | CONDENSED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
| NO20084256L (no) | DPP IV inhibitorformuleringer | |
| MA32175B1 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
| NO20051406L (no) | Indolderivater som beta-2 agonister | |
| NO20072286L (no) | Hemming av HCV NS3-NS4A-protease | |
| EA201170520A1 (ru) | Ингибитор p38 mapk-киназы | |
| WO2008074824A3 (en) | Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd) | |
| NO20054957L (no) | Subtituerte karboksylsyrer | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |